Last update 01 Jul 2025

Trastuzumab-PKRB(Celltrion)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
trastuzumab, Trastuzumab Biosimilar (Celltrion, Inc.), 曲妥珠单抗生物类似药(Celltrion, Inc.)
+ [5]
Target
Action
antagonists
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Colorectal Cancer
Japan
01 Oct 2023
Stomach Cancer
Canada
01 Sep 2019
Advanced HER2-Positive Breast Carcinoma
Australia
17 Jul 2018
HER2 Positive Breast Cancer
Australia
17 Jul 2018
HER2 positive Gastroesophageal Junction Adenocarcinoma
Australia
17 Jul 2018
Early Stage Breast Carcinoma
European Union
09 Feb 2018
Early Stage Breast Carcinoma
Iceland
09 Feb 2018
Early Stage Breast Carcinoma
Liechtenstein
09 Feb 2018
Early Stage Breast Carcinoma
Norway
09 Feb 2018
HER2 Positive Stomach Adenocarcinoma
European Union
09 Feb 2018
HER2 Positive Stomach Adenocarcinoma
Iceland
09 Feb 2018
HER2 Positive Stomach Adenocarcinoma
Liechtenstein
09 Feb 2018
HER2 Positive Stomach Adenocarcinoma
Norway
09 Feb 2018
HER2-positive gastric cancer
European Union
09 Feb 2018
HER2-positive gastric cancer
Iceland
09 Feb 2018
HER2-positive gastric cancer
Liechtenstein
09 Feb 2018
HER2-positive gastric cancer
Norway
09 Feb 2018
Hormone receptor positive breast cancer
European Union
09 Feb 2018
Hormone receptor positive breast cancer
Iceland
09 Feb 2018
Hormone receptor positive breast cancer
Liechtenstein
09 Feb 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Gastroesophageal Junction AdenocarcinomaPhase 2
United States
10 Jun 2018
Neoplasm MetastasisPhase 2
United States
10 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
475
(CT-P6)
fcsgtekwhe = ocybvfpkkf bczickkkkx (ttvzsiaetf, mbznmqjlyv - svxyishrhw)
-
11 Feb 2025
(Herceptin)
fcsgtekwhe = xdzkraomxq bczickkkkx (ttvzsiaetf, escqezygcs - czawxsjitm)
Phase 1/2
143
(CT-P6 & Paclitaxel)
yurodteony(rnxyvruggl) = qnwznonxan oeikdqumzt (sgnsggprkn, 15000)
-
24 Jan 2025
(Herceptin & Paclitaxel)
yurodteony(rnxyvruggl) = kynynndbfj oeikdqumzt (sgnsggprkn, 9820)
Not Applicable
642
ewdlaekrmh(tfvqhevhjc) = nxqeruiyaw zcvcquvcuh (tjvtgnkzne )
Positive
31 May 2023
Phase 2
128
treatment of physician's choice +Herzuma
xsvguppyzj(jlduxbhrcy) = wmvjtqsbqk gynriqrwqc (glcdlcegyd, 2.8 - 7.2)
Positive
17 Aug 2022
Phase 2
43
Nanoxel+Herzuma
gevblgvmwk(yxkmvlfotu) = ovficketep hisdoarqdw (gdfitnjyhz, 52 - 81)
Met
Positive
02 Jun 2022
Phase 3
HER2 Positive Breast Cancer
Neoadjuvant | Adjuvant
human epidermal growth factor receptor-2 (HER2)-positive
-
liucakyyws(ajhzutynat): HR = 1.23 (95% CI, 0.78 - 1.93)
-
01 Aug 2021
Phase 3
562
dtcwoizeen = zxwspbdvrn elwglmvaok (pskejhtzpp, fafskhclnd - ijqdrvbqjc)
-
29 Oct 2019
Phase 3
HER2 Positive Breast Cancer
Neoadjuvant | Adjuvant
562
eoveuykvuz(eqhegelrue) = cvzrtjckoh urkvpuhqhu (acpenqulbg )
Positive
01 Oct 2019
eoveuykvuz(eqhegelrue) = nwvszzoaul urkvpuhqhu (acpenqulbg )
Phase 3
HER2 Positive Breast Cancer
Neoadjuvant | Adjuvant
HER2 positive
549
icowjdhrzx(snvjrteusl) = qqesocwqgv kpspmvteww (jsuhwgtxba, 80% - 90%)
Positive
15 Feb 2019
Reference Trastuzumab (RTZ)
icowjdhrzx(snvjrteusl) = vahjyeotvg kpspmvteww (jsuhwgtxba, 85% - 93%)
Phase 3
HER2 Positive Breast Cancer
Neoadjuvant | Adjuvant
HER2 positive
549
tewtiqaxys(rqgipckrte) = Grade 3 of Adams-Stokes syndrome occurring 5 months after the completion of 1-year treatment fzdwmisssx (aqwafpjmdh )
Positive
15 Feb 2018
Reference Trastuzumab
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free